Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Precision Biosciences Inc
(NQ:
DTIL
)
9.280
-0.130 (-1.38%)
Streaming Delayed Price
Updated: 1:00 PM EDT, Jul 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Precision Biosciences Inc
< Previous
1
2
3
4
5
Next >
Precision BioSciences Announces its Addition to the Russell Microcap® Index
July 01, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025
June 27, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., MPH, as PBGENE-HBV Program Nears Clinical Readiness
June 20, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Presents New Preclinical Safety Data for PBGENE-HBV Clinical Candidate at the European Association for the Study of the Liver Congress
June 05, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Participate in Upcoming June Investor Conferences
May 30, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
May 17, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
May 13, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement
May 08, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Report First Quarter Results on May 13, 2024
May 07, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE’s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
May 07, 2024
From
Precision BioSciences
Via
Business Wire
Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024
May 01, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
April 16, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
March 27, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024
March 20, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy
March 19, 2024
From
Precision BioSciences
Via
Business Wire
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency
March 06, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants
March 01, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants
February 29, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences
February 20, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV as it Advances Towards Clinical Readiness
February 14, 2024
From
Precision BioSciences
Via
Business Wire
Precision BioSciences Promotes Naresh Tanna to Vice President of Investor Relations
February 13, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases
February 12, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Effect a Reverse Stock Split
February 09, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases
January 09, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Approval of First Clinical Trial Application of ARCUS Gene Insertion Program by Partner iECURE
December 13, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Publication in Nature Metabolism Supporting ARCUS® In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases
December 04, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Present at Hep-DART 2023
November 30, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
November 28, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
Sidoti Events, LLC’s Virtual November Micro-Cap Conference
November 14, 2023
Via
ACCESSWIRE
Precision BioSciences Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD’s The Liver Meeting 2023
November 13, 2023
From
Precision BioSciences, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.